In agreement with this prediction, the rotenone derivative deguelin suppressed tumour growth in a prostate cancer mouse model lacking both PTEN and Trp53. 72 Overall, these data provide evidence that targeting oxidative phosphorylation might be an effective therapeutic approach for prostate cancer. The gene discussed is PTEN; the disease is Familial prostate cancer.